Market Overview:
The global leukemia treatment drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of leukemia, rising awareness about leukemia and its treatments, and the launch of novel therapies for leukemia. Based on type, the global leukemia treatment drugs market is segmented into five categories: Gleevec, Sapacitabine, GA101, Vasaroxine Tosedosat Revlimid Bosutinib. Gleevec is currently one of the most popular drugs used for treating chronic myeloid leukaemia (CML) and gastrointestinal stromal tumors (GISTs). It accounted for a major share of the global market in 2017. However, over time there has been an increase in competition from other therapies such as Sapacitabine GA101 Vasaroxine Tosedosat Revlimid Bosutinib which are also being used to treat CML and GISTs. These newer therapies are expected to witness high growth rates during the forecast period owing to their better efficacy profiles compared with older therapies such as Gleevec. Based on application, hospitals accounted for a majority share of the global market in 2017 followed by research institutes diagnostic centers.
Product Definition:
Leukemia Treatment Drugs are used to treat leukemia, a type of cancer that affects the blood and bone marrow. Leukemia Treatment Drugs work by killing cancer cells or stopping them from growing.
Gleevec:
Gleevec (Imatinib) is a drug used for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. Chronic myeloid leukemia or CML is a cancer of the blood and bone marrow, which produces too many malignant cells in the body.
Sapacitabine:
Sapacitabine (Zerumbone) is an injectable cancer medication. It was developed by Pfizer and was first approved in 2007 in the U.S as a treatment for advanced stage Lymphoma and then expanded to cover multiple myeloma as well in 2009. The drug has not been approved by the FDA for use as a leukemia treatment drug yet, but there are clinical trials ongoing to evaluate its use against acute lymphoblastic leukemia (ALL).
Application Insights:
Based on the application, the global leukemia treatment drugs market is segmented into hospitals, research institutes, diagnostic centers and others. Hospitals held the largest share in 2017 owing to availability of advanced healthcare facilities and highly skilled medical staff at prime locations throughout Europe and North America.
The presence of a large number of cancer patients requiring chemotherapy & radiation therapy as well as stem cell transplantation drives demand for these drugs in this segment. Moreover, increasing awareness about these therapies among people living with acute leukemias is expected to fuel growth over the forecast period.
Rising prevalence of chronic myelogenous leukemia (CML) across developed countries including U.S.
Regional Analysis:
North America dominated the global market in 2017 owing to favorable government initiatives, increasing healthcare expenditure, and availability of effective treatment methods. Moreover, high incidence rate of chronic leukemia is also driving the regional market. According to NCBI; around 13000 new cases were registered in U.S.
Growth Factors:
- Increasing incidence of leukemia
- Growing awareness about leukemia and its treatment options
- Rising demand for targeted therapies for leukemia patients
- Technological advancements in the field of leukemia treatment drugs 5. Availability of government funding for research on new leukemia drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Leukemia Treatment Drugs Market Research Report
By Type
Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat, Revlimid, Bosutinib
By Application
Hospitals, Research Institutes, Diagnostic Centers, Others
By Companies
GSK, Pfizer, Novartis AG, Roche, Celgene, Biogen, Genzyme Corporation, Eisai C., Bristol Myers Squibb Company (BMS)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
225
Number of Tables & Figures
158
Customization Available
Yes, the report can be customized as per your need.
Global Leukemia Treatment Drugs Market Report Segments:
The global Leukemia Treatment Drugs market is segmented on the basis of:
Types
Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat, Revlimid, Bosutinib
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Research Institutes, Diagnostic Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK
- Pfizer
- Novartis AG
- Roche
- Celgene
- Biogen
- Genzyme Corporation
- Eisai C.
- Bristol Myers Squibb Company (BMS)
Highlights of The Leukemia Treatment Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Gleevec
- Sapacitabine
- GA101
- Vasaroxine
- Tosedosat
- Revlimid
- Bosutinib
- By Application:
- Hospitals
- Research Institutes
- Diagnostic Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Leukemia Treatment Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Leukemia treatment drugs are medications that help to treat leukemia. These drugs can be used alone or in combination with other treatments.
Some of the major companies in the leukemia treatment drugs market are GSK, Pfizer, Novartis AG, Roche, Celgene, Biogen, Genzyme Corporation, Eisai C., Bristol Myers Squibb Company (BMS).
The leukemia treatment drugs market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Leukemia Treatment Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Leukemia Treatment Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Leukemia Treatment Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Leukemia Treatment Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Leukemia Treatment Drugs Market Size & Forecast, 2018-2028
4.5.1 Leukemia Treatment Drugs Market Size and Y-o-Y Growth
4.5.2 Leukemia Treatment Drugs Market Absolute $ Opportunity
Chapter 5 Global Leukemia Treatment Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Leukemia Treatment Drugs Market Size Forecast by Type
5.2.1 Gleevec
5.2.2 Sapacitabine
5.2.3 GA101
5.2.4 Vasaroxine
5.2.5 Tosedosat
5.2.6 Revlimid
5.2.7 Bosutinib
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Leukemia Treatment Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Leukemia Treatment Drugs Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Research Institutes
6.2.3 Diagnostic Centers
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Leukemia Treatment Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Leukemia Treatment Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Leukemia Treatment Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Leukemia Treatment Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Leukemia Treatment Drugs Market Size Forecast by Type
9.6.1 Gleevec
9.6.2 Sapacitabine
9.6.3 GA101
9.6.4 Vasaroxine
9.6.5 Tosedosat
9.6.6 Revlimid
9.6.7 Bosutinib
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Leukemia Treatment Drugs Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Research Institutes
9.10.3 Diagnostic Centers
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Leukemia Treatment Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Leukemia Treatment Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Leukemia Treatment Drugs Market Size Forecast by Type
10.6.1 Gleevec
10.6.2 Sapacitabine
10.6.3 GA101
10.6.4 Vasaroxine
10.6.5 Tosedosat
10.6.6 Revlimid
10.6.7 Bosutinib
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Leukemia Treatment Drugs Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Research Institutes
10.10.3 Diagnostic Centers
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Leukemia Treatment Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Leukemia Treatment Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Leukemia Treatment Drugs Market Size Forecast by Type
11.6.1 Gleevec
11.6.2 Sapacitabine
11.6.3 GA101
11.6.4 Vasaroxine
11.6.5 Tosedosat
11.6.6 Revlimid
11.6.7 Bosutinib
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Leukemia Treatment Drugs Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Research Institutes
11.10.3 Diagnostic Centers
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Leukemia Treatment Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Leukemia Treatment Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Leukemia Treatment Drugs Market Size Forecast by Type
12.6.1 Gleevec
12.6.2 Sapacitabine
12.6.3 GA101
12.6.4 Vasaroxine
12.6.5 Tosedosat
12.6.6 Revlimid
12.6.7 Bosutinib
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Leukemia Treatment Drugs Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Research Institutes
12.10.3 Diagnostic Centers
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Leukemia Treatment Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Leukemia Treatment Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Leukemia Treatment Drugs Market Size Forecast by Type
13.6.1 Gleevec
13.6.2 Sapacitabine
13.6.3 GA101
13.6.4 Vasaroxine
13.6.5 Tosedosat
13.6.6 Revlimid
13.6.7 Bosutinib
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Leukemia Treatment Drugs Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Research Institutes
13.10.3 Diagnostic Centers
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Leukemia Treatment Drugs Market: Competitive Dashboard
14.2 Global Leukemia Treatment Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GSK
14.3.2 Pfizer
14.3.3 Novartis AG
14.3.4 Roche
14.3.5 Celgene
14.3.6 Biogen
14.3.7 Genzyme Corporation
14.3.8 Eisai C.
14.3.9 Bristol Myers Squibb Company (BMS)
